Mutational analysis of block and facilitation of HERG current by A Class III anti-arrhythmic agent, nifekalant

Channels

Volumn 1, Issue 3, 2007, Pages 198-208

  Hosaka, Yukio ^a,d   Iwata, Miki ^a   Kamiya, Narutoshi ^e   Yamada, Mitsuhiko ^a,f   Kinoshita, Kengo ^g,h   Fukunishi, Yoshifumi ⁱ   Tsujimae, Kenji ^a   Hibino, Hiroshi ^a   Aizawa, Yoshifusa ^d   Inanobe, Atsushi ^a   Nakamura, Haruki ^b,c   Kurachi, Yoshihisa ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b The Center for Advanced Medical Engineering and Informatics (MEI Center)   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Science and Technology Agency   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Anti arrhythmic agent; Docking simulation; Facilitation; HERG; Nifekalant; Potassium channel

Indexed keywords

ANTIARRHYTHMIC AGENT; KCNH2 PROTEIN, HUMAN; NIFEKALANT; POTASSIUM; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PYRIMIDINONE DERIVATIVE;

ANIMAL; ARTICLE; CELL MEMBRANE POTENTIAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECT; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MUTATION; OOCYTE; PROTEIN CONFORMATION; SITE DIRECTED MUTAGENESIS; TIME; XENOPUS LAEVIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; COMPUTER SIMULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE TRANSFER TECHNIQUES; HUMANS; MEMBRANE POTENTIALS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; OOCYTES; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; PROTEIN CONFORMATION; PYRIMIDINONES; TIME FACTORS; XENOPUS LAEVIS;

EID: 53049102635     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.4691     Document Type: Article

References (45)

1. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
2. Trudeau MC, W.Warmke J, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269:92-5.
3. Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000; 11:938-40.
4. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440:463-9.
5. Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA 1996; 93:2208-12.
6. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109:157-63.
7. Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res 1996; 31:963-74.
8. Kushida S, Ogura T, Komuro I, Nakaya H. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: Mode of action. Eur J Pharmacol 2002; 457:19-27.
9. Carmeliet E. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ Res 1993; 73:857-68.
10. Jiang M, Dun W, Fan FS, Tseng GN. Use-dependent agonist effect of azimilide on the HERG channel. J Pharmacol Exp Ther 1999; 291:1324-36.
11. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97:12329-33.
12. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 2004; 66:240-9.
13. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS. Drug binding interactions in the inner cavity of hERG channels: Molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 2006; 69:509-19.
14. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the hERG channel drug binding site. J Biol Chem 2004; 279:10120-7.
15. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular determinants of hERG channel block. Mol Pharmacol 2006; 69:1709-16.
16. Chachin M, Katayama Y, Yamada M, Horio Y, Ohmura T, Kitagawa H, Uchida S, Kurachi Y. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel. Eur J Pharmacol 1999; 374:457-60.
17. Stühmer W. Electrophysiological recording from Xenopus oocytes. Methods Enzymol 1998; 280-300.
18. Fiser A, Ŝali A. Modeller: Generation and refinement of homology-based protein structure models. Methods Enzymol 2003; 461-91.
19. Jiang Y, Lee A, Chen J, Ruta V, Cadene M, Chait BT, MacKinnon R. X-ray structure of a voltage-dependent K+ channel. Nature 2003; 423:33-41.
20. Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem 2000; 21:1049-74.
21. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL, Dupuis M, Montgomery Jr JA. General atomic and molecular electronic structure system. J Comput Chem 1993; 14:1347-63.
22. Fukunishi Y, Mikami Y, Nakamura H. Similarities among receptor pockets and among compounds: Analysis and application to in silico ligand screening. J Mol Graph Model 2005; 24:34-45.
23. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996; 379:833-6.
24. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005; 10:149-55.
25. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002; 301:427-34.
26. Cavalli A, Poluzzi E, Ponti FD, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K+ channel blockers. J Med Chem 2002; 45:3844-53.
27. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shcekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003; 13:1829-35.
28. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol Pharmacol 2000; 57:367-74.
29. Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC. Open channel block of HERG K+ channels by vesnarinone. Mol Pharmacol 2001; 60:244-53.
30. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, Mitcheson JS. The low-potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping. Mol Pharmacol 2004; 66:1201-12.
31. MacKinnon R. Potassium channels. FEBS Letter 2003; 555:62-5.
32. Volders PGA, Stengl M, van Opstal JM, Gerlach U, Spätjens RLHMG, Beekman JDM, Sipido KR, Vos MA. Probing the contribution of IKs to canine ventricular repolarization: Key role for adrenergic receptor stimulation. Circulation 2003; 107:2753-60.
33. Yamada M. Adrenergic modulation of prepulse facilitation of L-type calcium channels in rabbit ventricular myocytes. Pfügers Arch 2002; 444:89-98.
34. Yuill KH, Convery MK, Dooley PC, Doggrell SA, Hancox JC. Effects of BDF 9198 on action potentials and ionic currents from guinea-pig isolated ventricular myocytes. Br J Pharmacol 2000; 130:1753-66.
35. Spencer CI, Yuill KH, Borg JJ, Hancox JC, Kozlowski RZ. Actions of pyrethroid Insecticides on sodium currents, action ptentials, and contractile rhyrhm in isolated mammalian ventricular myocytes and perfused heart. J Pharmacol Exp Ther 2001; 298:1067-82.
36. Hess P, Lansman JB, Tsien RW. Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature 1984; 311:538-44.
37. Tan J, Liu Z, Wang R, Huang ZY, Chen AC, Gurevitz M, Dong K. Identification of amino acid residues in the insect sodium channel critical pyrethroid binding. Mol Pharmacol 2004; 67:513-22.
38. Hockerman HG, Peterson ZB, Johnson DB, Catterall AW. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 1997; 37:361-96.
39. Yoshida T, Inoue R, Morii T, Takahashi N, Yamamoto S, Hara Y, Tominaga M, Shimizu S, Sato Y, Mori Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat Chem Biol 2006; 2:596-607.
40. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58:107-15.
41. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, Nakashima M. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23:674-80.
42. Friedrichs GS, Chi L, Gralinski MR, Black SC, Basler GC, Mu DX, Pewitt SR, Johnson CR, Lucchesi BR. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol 1995; 25:314-23.
43. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrythmias. - post-marketing special investigation-. Circ J 2005; 69:1237-43.
44. Takenaka K, Yasuda S, Miyazaki S, Kurita T, Sutani Y, Morii I, Daikoku S, Kamakura S, Nonogi H. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65:60-2.
45. Hua F, Gilmour Jr RF. Contribution of IKr to rate-dependent action potential dynamics in canine endocardium. Circ Res 2004; 94:810-9.